Avaliação da atividade anti-inflamatória intestinal do óleo de Bertholletia excelsa Bonpl.
Carregando...
Data
2018-02-27
Autores
Mori, Cristiane
Título da Revista
ISSN da Revista
Título de Volume
Editor
Universidade Estadual Paulista (Unesp)
Resumo
O termo Doença Inflamatória Intestinal (DII) compreende duas doenças, a Retocolite Ulcerativa (RCU) e a Doença de Crohn (DC), caracterizadas por inflamação crônica que compromete o trato gastrointestinal. Estudos mostram que o estresse oxidativo é um dos fatores determinantes para o desenvolvimento da DII. A terapêutica atual não proporciona cura permanente, demonstrando a necessidade de novas estratégias terapêuticas. A espécie Bertholletia excelsa (Lecythidaceae), popularmente conhecida como castanha-do-pará, é uma árvore nativa da Floresta Amazônica; de seu fruto retira-se a castanha, semente oleaginosa com alto teor de ácidos graxos, selênio e outros componentes como vitaminas e minerais, que podem apresentar atividade farmacológica associada a efeitos benéficos. Devido à sua composição, o objetivo do presente estudo foi avaliar a atividade anti-inflamatória da castanha-do-pará como potencial terapia adjuvante para o tratamento da DII. Ratos Wistar receberam por via oral cinco doses do óleo (18,75; 37,5; 75; 150 e 300 mg/kg) durante 5 dias consecutivos. Após o tratamento, foi feita indução do processo inflamatório por meio da administração via retal de 0,25 mL de solução contendo 10 mg de TNBS em etanol a 50% (v/v). Após 72h da indução do processo inflamatório, os animais foram mortos e os cólons retirados para análises macroscópicas (tamanho e escore da lesão, relação peso-comprimento colônico) e bioquímicas tais como atividade das enzimas mieloperoxidase (MPO) e fosfatase alcalina (FA), e níveis de glutationa total. As doses de 75 e 150 mg/kg do óleo de castanha-do-pará melhoraram a relação peso-comprimento colônico em comparação ao grupo controle. A dose de 150mg/kg também apresentou melhora no tamanho da lesão em comparação ao grupo controle. O tratamento também não recuperou a atividade da MPO e FA, mas evitou a depleção dos níveis cólicos de glutationa nas doses de 18,75 e 37,5 mg/kg, mantendo-os semelhantes aos dos animais saudáveis. Os resultados, em conjunto, não indicam atividade anti-inflamatória nas doses testadas.
Inflammatory Bowel Disease (IBD) is a term that comprises two disorders, Ulcerative Colitis (UC) and Crohn’s Disease (DC), which are chronic inflammation that compromise the gastrointestinal tract. Studies show that the oxidative stress is one of the many factors involved in DII pathogenesis. The pharmacological treatment doesn’t bring cure, highlighting the necessity of new therapeutical strategies. The species Bertholletia excelsa Bonpl. (Lecythidaceae), popularly known as Brazil nut, is a native tree from the amazon rainforest. From its fruit is removed a oilseed with high contents of fatty acids, selenium and another components such vitamins and minerals, that can produce pharmacological activity associated with beneficial effects. Due to its composition, the objective of this project was to evaluate the anti-infammatory activity of the Brazil nut oil as a potential adjuvant therapy for the treatment of IBD. Male wistar rats received orally five dosis of oil (18,75; 37,5; 75; 150 e 300 mg/kg) through five consecutive days. After treatment the inflammatory process was induced by rectally administration of 0,25 mL of a solution containing 10 mg of TNBS diluted in ethanol 50% (v/v). Seventy two hours after induction of the inflammatory process, the animals were killed and the colons removed for macroscopic (size and score of lesion, weight/length ratio) and biochemical analysis such as activity of the enzimes myeloperoxidase (MPO) and alkaline phosphatase (AP), and total levels of glutathione. The 75 mg/kg and 150 mg/kg doses of the oil ameliorated the weight/length ration in comparison with the control group. The 150 mg/kg dose also ameliorated the size of lesion in comparison with the control group. The treatment didn’t recovered the activity of the enzymes MPO and AP, but prevented the depletion of colonic levels of glutathione in the 18,75 mg/kg and 37,5 mg/kg doses. The results of the glutathione levels in these doses were similar to the healthy group. The results, in conjoint, didn’t indicate the anti-inflammatory activity on the tested doses.
Inflammatory Bowel Disease (IBD) is a term that comprises two disorders, Ulcerative Colitis (UC) and Crohn’s Disease (DC), which are chronic inflammation that compromise the gastrointestinal tract. Studies show that the oxidative stress is one of the many factors involved in DII pathogenesis. The pharmacological treatment doesn’t bring cure, highlighting the necessity of new therapeutical strategies. The species Bertholletia excelsa Bonpl. (Lecythidaceae), popularly known as Brazil nut, is a native tree from the amazon rainforest. From its fruit is removed a oilseed with high contents of fatty acids, selenium and another components such vitamins and minerals, that can produce pharmacological activity associated with beneficial effects. Due to its composition, the objective of this project was to evaluate the anti-infammatory activity of the Brazil nut oil as a potential adjuvant therapy for the treatment of IBD. Male wistar rats received orally five dosis of oil (18,75; 37,5; 75; 150 e 300 mg/kg) through five consecutive days. After treatment the inflammatory process was induced by rectally administration of 0,25 mL of a solution containing 10 mg of TNBS diluted in ethanol 50% (v/v). Seventy two hours after induction of the inflammatory process, the animals were killed and the colons removed for macroscopic (size and score of lesion, weight/length ratio) and biochemical analysis such as activity of the enzimes myeloperoxidase (MPO) and alkaline phosphatase (AP), and total levels of glutathione. The 75 mg/kg and 150 mg/kg doses of the oil ameliorated the weight/length ration in comparison with the control group. The 150 mg/kg dose also ameliorated the size of lesion in comparison with the control group. The treatment didn’t recovered the activity of the enzymes MPO and AP, but prevented the depletion of colonic levels of glutathione in the 18,75 mg/kg and 37,5 mg/kg doses. The results of the glutathione levels in these doses were similar to the healthy group. The results, in conjoint, didn’t indicate the anti-inflammatory activity on the tested doses.
Descrição
Palavras-chave
Doença Inflamatória Intestinal, Atividade anti-inflamatória, Castanha-do-pará, Inflammatory Bowel Disease, Brazil nut, anti-inflammatory